Pfizer (PFE) closed the latest trading day at $25.23, indicating a -1.33% change from the previous session's end. The stock's change was less than the S&P 500's daily gain of 0.82%. Meanwhile, the Dow ...

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Pfizer has a diversified portfolio, including successful vaccines and promising new drugs. Read more to see why I upgrade PFE ...

Guggenheim lowered the firm’s price target on Pfizer (PFE) to $33 from $35 and keeps a Buy rating on the shares. Pfizer will be releasing their ...

Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health ...

Health care companies are taking a step back to better understand patients' experiences after a powerful U.S. health ...

Luigi Mangione, the 26-year-old accused in the killing of UnitedHealthcare CEO Brain Thompson, will plead not guilty, his ...

A Topeka-based aviation company housed at Forbes Field is expanding, with the help of the Topeka and Shawnee County’s ...

Cardiff Oncology CRDF announced robust efficacy data from an ongoing mid-stage study evaluating two doses of its lead ...

The FDA bestows a Fast Track designation to Sanofi's two combination vaccine candidates to prevent influenza and COVID-19 infections.

Pfizer's share price struggles despite a strong asset portfolio and $10 billion annual R&D investment, with ongoing Seagen ...